API purity is one of the most important quality considerations for pharmaceutical manufacturers sourcing active pharmaceutical ingredients. CAS No 1260141-27-2 manufacturers in India and international API suppliers must maintain appropriate controls to ensure that material meets established specifications for identity, purity and quality. CAS No. 1260141-27-2 is associated with Vonoprazan Fumarate, the fumarate salt form of vonoprazan, a potassium-competitive acid blocker used in pharmaceutical products.
What Is CAS No. 1260141-27-2?
CAS No. 1260141-27-2 is an identifier associated with Vonoprazan Fumarate. PubChem lists Vonoprazan Fumarate under this CAS number and provides its molecular formula as C21H20FN3O6S and molecular weight as approximately 461.5 g/mol. Vonoprazan Fumarate is the fumarate salt of vonoprazan and is associated with potassium-competitive inhibition of the gastric H+/K+-ATPase proton pump.
For pharmaceutical manufacturers, identifying the correct chemical substance is only the starting point. The material must also comply with appropriate specifications established for its intended pharmaceutical application. These specifications can address assay, impurities, residual solvents, physical characteristics and other relevant quality attributes.
Why Does API Purity Matter?
The purity of an API can directly influence the quality and consistency of pharmaceutical manufacturing. An API containing unwanted impurities or inconsistent levels of the active substance may create challenges during formulation, analytical testing and regulatory assessment.
For this reason, pharmaceutical manufacturers generally establish defined acceptance criteria for drug substances. FDA’s guidance on active pharmaceutical ingredients states that appropriate specifications should be established for APIs and should include controls for impurities such as organic impurities, inorganic impurities and residual solvents where applicable.
Purity should therefore not be considered simply as a single percentage reported on a certificate. A comprehensive quality assessment considers the identity of the material, assay, impurity profile and other parameters relevant to the API’s intended use.
Understanding Impurity Control
Impurity control is an important part of pharmaceutical API manufacturing. Impurities can originate from starting materials, intermediates, reagents, solvents, manufacturing processes, degradation or changes in process conditions.
For Vonoprazan Fumarate, regulatory documentation demonstrates the importance of controlling impurities through appropriate specifications and analytical methods. FDA’s chemistry review of vonoprazan fumarate describes characterization of the drug substance using techniques including NMR, mass spectrometry, UV, IR, elemental analysis and X-ray diffractometry. The review also notes that appropriate impurity acceptance criteria were established and evaluated.
A controlled impurity profile helps manufacturers monitor whether the production process remains consistent over time. FDA’s ICH Q7 guidance recommends establishing an impurity profile for APIs and comparing it at appropriate intervals with regulatory or historical data to identify changes associated with raw materials, equipment or manufacturing processes.
How Is API Purity Evaluated?
Determining API purity involves analytical testing rather than relying solely on appearance or supplier declarations. Pharmaceutical manufacturers and qualified laboratories use validated or otherwise appropriate analytical procedures to assess whether an API conforms to its established specifications.
Depending on the applicable specification, testing can address:
- Assay or active-content determination
- Related substances and organic impurities
- Residual solvents
- Water or moisture content
- Identification
- Physical characteristics
- Elemental impurities, where applicable
- Microbiological quality, where specified
The exact tests and acceptance limits depend on the applicable specification, regulatory requirements and intended pharmaceutical use. FDA guidance states that each batch of API should undergo appropriate laboratory testing to determine conformance with specifications.
Importance of Batch-to-Batch Consistency
High API purity in one batch is not enough for long-term pharmaceutical manufacturing. Consistency between batches is equally important because manufacturers need predictable raw materials for ongoing production.
A reliable manufacturing process should therefore incorporate controls for critical process parameters, raw materials, intermediates and analytical testing. Changes in raw materials, equipment or production conditions can potentially affect an API’s impurity profile, which is why ongoing monitoring is an important element of pharmaceutical quality management.
For companies evaluating CAS No 1260141-27-2 manufacturers in India, examining evidence of consistent batch quality can therefore be an important part of supplier qualification.
The Role of Certificates of Analysis
A Certificate of Analysis (COA) provides documented information about the quality testing performed on a particular API batch. According to FDA’s ICH Q7 guidance, an authentic COA should identify the API and batch, provide the applicable tests and acceptance limits, and report numerical results where appropriate. It should also be dated and authorized by the relevant quality unit.
Buyers should review COAs carefully rather than focusing on a single assay value. Comparing assay, impurity results and other quality parameters across multiple batches can provide useful information about manufacturing consistency.
Choosing a Reliable API Manufacturer
Supplier qualification is an important component of pharmaceutical procurement. Manufacturers purchasing CAS No. 1260141-27-2 should evaluate more than price and availability. Quality systems, analytical capabilities, manufacturing controls, documentation and supply reliability can all be relevant.
FDA’s API GMP guidance emphasizes that quality management should involve documented procedures, appropriate quality units, laboratory controls and review of batch records before API release. It also recommends that suppliers of critical materials be evaluated and approved through an appropriate quality system.
For pharmaceutical buyers considering CAS No 1260141-27-2 manufacturers in India, these principles can provide a useful framework for evaluating potential suppliers. Buyers can request relevant technical documentation, review specifications, assess quality-control capabilities and establish requirements before beginning commercial supply.
Supporting Consistent Pharmaceutical Manufacturing
API purity is ultimately part of a broader quality system. Reliable raw-material sourcing, controlled manufacturing processes, appropriate analytical testing and complete documentation work together to support consistent pharmaceutical production.
For CAS No. 1260141-27-2, understanding the relationship between identity, assay, impurities and overall quality can help pharmaceutical manufacturers make more informed sourcing decisions. Working with a qualified CAS No 1260141-27-2 manufacturer in India that maintains appropriate quality systems can support dependable API procurement and help establish a stronger foundation for pharmaceutical manufacturing.
As pharmaceutical supply chains become increasingly global, manufacturers should place quality, consistency and documentation at the center of API supplier evaluation. A structured approach to qualification can help buyers identify suppliers capable of meeting their technical and regulatory requirements while supporting reliable long-term supply.
Other Recommendations: Vonoprazan Fumarate API exporters in India